COMBINATION OF DAROLUTAMIDE WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL INCREASES SURVIVAL FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN THE PHASE 3 ARASENS STUDY

被引：0

作者：

Olivier, Kara ^{[1
]}

Tombal, Betrand ^{[2
]}

Thiele, Silke ^{[3
]}

Li, Rui ^{[4
]}

Joensuu, Heikki ^{[5
]}

Smith, Matthew ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] Clin Univ St Luc, Brussels, Belgium

[3] Bayer AG, Berlin, Germany

[4] Bayer HealthCare Inc, Whippany, NJ USA

[5] Orion Pharma, Espoo, Finland

来源：

ONCOLOGY NURSING FORUM | 2022年 / 49卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P386

引用

页码：20 / 20

页数：1

共 50 条

[1] Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in the Phase 3 ARASENS Study
Hovey, Elizabeth
Hussain, Maha
Tombal, Bertrand
Saad, Fred
Fizazi, Karim
Sternberg, Coran
Crawford, E. David
Shore, Neal
Kopyltsov, Evgeny
Rezazadeh Kalebasty, Arash
Bogemann, Martin
Ye Dingwei
Cruz, Felipe
Suzuki, Hiroyoshi
Verholen, Frank
Srinivasan, Shankar
Kuss, Iris
Joensuu, Heikki
Smith, Matthew R.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 64 - 64
[2] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
Todenhoefer, Tilman
Smith, Matthew R.
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, David
Kopyltsov, Evgeny
Park, Chandler H.
Alekseev, Boris
Pino, Alvaro Montesa
Ye, Dingwei
Parnis, Francis
Tammela, Teuvo
Suzuki, Hiroyoshi
Joensuu, Heikki
Thiele, Silke
Li, Rui
Kuss, Iris
Tombal, Bertrand
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 110 - 110
[3] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
Smith, Matthew Raymond
Hussain, Maha H. A.
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Kopyltsov, Evgeny
Park, Chandler H.
Alexeev, Boris
Montesa, Alvaro
Ye, Dingwei
Parnis, Francis
Cruz, Felipe Melo
Tammela, Teuvo
Suzuki, Hiroyoshi
Joensuu, Heikki
Thiele, Silke
Li, Rui
Kuss, Iris
Tombal, Bertrand F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[4] ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
Kumar, Naveen
INDIAN JOURNAL OF UROLOGY, 2022, 38 (03) : 238 - 239
[5] Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
Hussain, Maha
Tombal, Bertrand
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Shore, Neal
Kopyltsov, Evgeny
Kalebasty, Arash Rezazadeh
Boegemann, Martin
Ye, Dingwei
Cruz, Felipe
Suzuki, Hiroyoshi
Kapur, Shivani
Srinivasan, Shankar
Verholen, Frank
Kuss, Iris
Joensuu, Heikki
Smith, Matthew R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3595 - +
[6] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study
Kalebasty, Arash Rezazadeh
Hammerer, Peter
Tombal, Bertrand
Hussain, Maha
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, David
Zhang, Weijiang
Ploeger, Bart
Li, Rui
Kuss, Iris
Zieschang, Carsten
Wittemer-Rump, Sabine
Smith, Mathew
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 80 - 81
[7] Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
Rezazadeh, Arash
Tombal, Bertrand F.
Hussain, Maha H. A.
Saad, Fred
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Kapur, Shivani
Zhang, Weijiang
Ploeger, Bart
Li, Rui
Kuss, Iris
Zieschang, Carsten
Wittemer-Rump, Sabine
Smith, Matthew Raymond
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
Smith, Matthew Raymond
Saad, Fred
Hussain, Maha
Sternberg, Cora N.
Fizazi, Karim
Yamada, Karin Sayuri
Kappeler, Christian
Kuss, Iris
Tombal, Bertrand F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[9] Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
Saad, Fred
Vjaters, Egils
Shore, Neal
Olmos, David
Xing, Nianzeng
Pereira de Santana Gomes, Andrea Juliana
Cesar de Andrade Mota, Augusto
Salman, Pamela
Jievaltas, Mindaugas
Ulys, Albertas
Jakubovskis, Maris
Kopyltsov, Evgeny
Han, Weiqing
Nevalaita, Liina
Testa, Isabella
Le Berre, Marie-Aude
Kuss, Iris
Haresh, Kunhi Parambath
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (36)
[10] Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS
Tombal, B.
Smith, M. R.
Hussain, M.
Saad, F.
Fizazi, K.
Sternberg, C. N.
Crawford, E. D.
Kapur, S.
Zhang, W.
Ploeger, B.
Li, R.
Kuss, I.
Zieschang, C.
Wittemer-Rump, S.
Rezazadeh, Kalebasty A.
EUROPEAN UROLOGY, 2023, 83

← 1 2 3 4 5 →